Our internal pipeline is focused on creating antibody-drug conjugate and immune-oncology conjugate candidates, including ARX788: our most advanced internal ADC candidate currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor trials. We have established collaborations with multiple pharmaceutical companies in additional therapeutic areas, including metabolic disorders and cardiovascular disease.
Our team of dedicated professionals is bound by a culture and vision that embraces innovation, practicality and accountability. Through these shared values, we are able to relentlessly pursue our mission of bringing engineered precision biologics to patients facing the need for new treatment options. Visit our Careers page for information about joining our team.
EPBs are therapies we create using our expanded genetic code technology platform. Harnessing the power of this proprietary technology, we are able to precisely incorporate novel synthetic amino acids (SAA) in proteins, all within a living cell. The result is product candidates specifically designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation – offering potential safety and efficacy benefits to patients.
Ambrx, Inc.
10975 North Torrey Pines Road
La Jolla, CA 92037
Tel: (858) 875-2400
Business Development
bd@ambrx.com
Expanded Access Inquiry
expanded.access@ambrx.com
Kate Hermans
Interim Chief Executive Officer
Member
Sonja Nelson
Chief Financial Officer
Janice Lu, M.D., Ph.D.
Chief Medical Officer
Shawn Zhang, Ph.D.
Executive Vice President of R&D Operations and General Manager of Ambrx China